Drugs / WTX-124
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05479812 | May 2022 → Jul 2026 overdue | metastatic neoplasm, neoplasm | Werewolf Therapeutics, Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 10
| Date | Issuer | Release |
|---|---|---|
| 2025-12-18 | Werewolf Therapeutics, Inc. | Results Werewolf Therapeutics Announces Pipeline and Business Updates werewolftx.com ↗
WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of post-ICI advanced or metastatic cutaneous melanoma patients, with potential best-in-class tolerability profile |
| 2025-11-07 | Werewolf Therapeutics, Inc. | Results Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting werewolftx.com ↗
These strategies are supported by first-in-kind pharmacokinetic data that provided a real-time assessment of WTX-124’s selective activation and immune engagement within the tumor. |
| 2025-10-08 | Werewolf Therapeutics, Inc. | Regulatory Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer werewolftx.com ↗
today announced that the Company has received Fast Track Designation for the use of WTX-124 for the potential treatment of patients with locally advanced or metastatic cutaneous melanoma after standard of care immunotherapy. |
| 2024-06-01 | Werewolf Therapeutics, Inc. | Results Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors werewolftx.com ↗
WTX-124 was shown to be clinically active and generally well-tolerated in patients who were relapsed/refractory to immune checkpoint inhibitor therapy |
| 2024-05-23 | Werewolf Therapeutics, Inc. | Results Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting werewolftx.com ↗
Updated single agent dose escalation data continues to demonstrate that WTX-124 is well tolerated and clinically active in patients with checkpoint inhibitor therapy relapsed/refractory cancers |
| 2023-11-14 | Werewolf Therapeutics, Inc. | Results Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update werewolftx.com ↗
Preliminary data from the WTX-124 monotherapy dose-escalation arm of the ongoing Phase 1/1b clinical trial provide compelling early evidence of dose-dependent anti-tumor and biomarker activity |
| 2023-11-03 | Werewolf Therapeutics, Inc. | Results Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting werewolftx.com ↗
Preliminary data support the potential of WTX-124 to be a differentiated next-generation IL-2 compound by showing immune cell activation in the tumor microenvironment (TME) and monotherapy clinical activity in an outpatient setting |
| 2022-08-11 | Werewolf Therapeutics, Inc. | Regulatory Werewolf Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights werewolftx.com ↗
During the second quarter of 2022, Werewolf received clearance from the U.S. Food and Drug Administration (FDA) on its Investigational New Drug (IND) application for WTX-124. |
| 2022-04-08 | Werewolf Therapeutics, Inc. | Results Werewolf Therapeutics Presents Promising Preclinical Data on its Two Lead INDUKINE™ Molecules at AACR 2022 Annual Meeting werewolftx.com ↗
WTX-124 demonstrated high tumor selectivity and generated significant anti-tumor activity in a CD8+ T cell-dependent manner |
| 2022-03-16 | Werewolf Therapeutics, Inc. | Results Werewolf Therapeutics Announces Publication of Data Demonstrating the Preclinical Efficacy of WTX-124 in Delivering IL-2 Selectively to the Tumor Microenvironment werewolftx.com ↗
The article, entitled “Discovery of a Conditionally Activated Interleukin-2 that Promotes Anti-tumor Immunity and Induces Tumor Regression,” includes preclinical data that demonstrate the efficacy of the design of WTX-124 in delivering IL-2 selectively to the tumor microenvironment where it stimulates a potent anti-tumor immune response. |
All press releases naming this drug 15 releases
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WTX-124 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05479812 ↗ |